Biocept acquisition

They should not be used to select a CPT Code for any particular test or patient. In these rearrangements, the anaplastic lymphoma kinase ALK gene is fused to the echinoderm microtubule-associated protein-like 4 EML4 gene.

Order a Test Requisition Form. The androgen receptor AR regulates the growth of prostate epithelial cells. For patients with metastatic prostate cancer or castration-resistant prostate cancer CRPCthe detection of AR expression can guide the selection of a personalized treatment strategy. For untreated prostate cancer, AR -positive tumors are more likely to respond to hormonal therapy i.

AR expression is also associated with other cancers, such as salivary duct carcinoma and triple negative breast cancer TNBC. Clinical investigators believe that the presence of circulating tumor cells CTCs in blood is an indicator of metastasis. Metastasis is a complex multistep process that includes epithelial-mesenchymal transition EMTin which tumor cells are characterized by loss of cell adhesion, repression of E-cadherin, acquisition of mesenchymal markers, increased cell motility, and invasiveness.

Init was shown that the BRAF gene is mutated in a range of human cancers. Detection of BRAF V mutations can predict response to anti-EGFR therapy in colon cancer, 8 determine prognosis in thyroid and colon cancers, 9 and inform the selection of targeted drug therapies e. Targeted drug therapies designed to treat cancers driven by BRAF mutations have demonstrated improvements in patient survival.

The epidermal growth factor receptor EGFR is a transmembrane receptor tyrosine kinase, and mutations in the EGFR gene are associated with a number of cancers, including colorectal, anal, head and neck, breast, ovarian, brain, prostate, and lung. These EGFR mutations typically affect the kinase domain, leading to its constitutive activation and uncontrolled cell division.

However, after 6—12 months, resistance to these targeted therapies inevitably emerges. EGFR is a member of the ErbB family of receptors that have been implicated in tumor progression of many cancer types. Thus, for patients with newly diagnosed or recurring metastatic breast cancer, the assessment of ER expression levels is standard of care, and accurate assessment can play a major role in treatment outcomes. This is because ER expression is a strong predictive factor for response to hormone therapies.

Several drugs have been developed that inhibit ERs in different ways. Importantly, these hormone therapies are recommended for women with ER -positive breast cancers, but they do not help women whose tumors lack ERs.

Fibroblast growth factor receptor 1 FGFR1 is one of four fibroblast growth factor receptors, which are involved in diverse cellular processes, such as cell division, cell growth and maturation, the formation of blood vessels, and wound healing.

In different types of lung cancer, such as adenocarcinoma, FGFR1 amplification is quite rare. These include highly selective FGFR1 inhibitors, and multi-kinase inhibitors. Only four agents have been approved by the FDA for use in cancer, although their approvals were not based on their activity against FGFR. Byantibody therapy targeting the HER2 pathway was shown to significantly improve progression-free and overall survival in metastatic disease.

However, not all patients with HER2 overexpression benefit from this widely used agent. These successes supported the launch of second-generation adjuvant trials testing single and dual HER2-targeted agents, administered concomitantly or sequentially with chemotherapy. Because of these efforts, HER2 -positive breast cancer is no longer associated with poor prognosis if HER2 -targeted therapies are administered. KRAS is a member of the Ras family of small GTPases, primarily regulating cell division by helping relay signals from the cell membrane to the nucleus.

Wildtype KRAS is a tumor suppressor that is frequently mutated during tumor progression. Activating mutations in the KRAS gene impair the ability of the KRAS protein to switch from the active to the inactive state, leading to constitutive activation, cell transformation, and increased resistance to cancer therapies namely, chemotherapy and therapies that target EGFR.

A number of drug classes have been developed that target clinically actionable proteins downstream of KRAS, but no currently available drug inhibits KRAS directly.

Activating the MET receptor in malignant cells activates a number of signaling transduction pathways, altering a number of biological process and driving metastasis. Multiple antibodies against MET and small molecule MET inhibitors are currently in clinical trials for the treatment of various cancer types. Several compounds targeting the MET pathway are under investigation in clinical trials. Determining which patient harbor MET mutations, and are therefore more likely to respond to MET kinase inhibitors, could contribute to better clinical outcomes.

Clinical studies have shown promise to MYC — pathway inhibition as a strategy for cancer treatment. The Trk family play important roles in neuronal development, maintenance, and protection of cells.Biocept, Inc. Nasdaq: BIOCa leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, after the market closes on Monday, March 29, The Company will host a conference call for the investment community to discuss the results and answer questions at p.

Eastern time p. Pacific time. Why It Matters: Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology. Smaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.

The following three companies have developed technology that could make them sought-after acquisition targets: BioMark Diagnostics Inc OTC: BMKDFa biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer.

The unique technology finds metabolomics biomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas. BioMark is pivoting into commercialization after many years in the research and development phase. On Feb. The collaboration will also support BioMark in setting up clinical lab services in Quebec.

BioMark plans to demonstrate its technology later in Biocept boasts 22 patents for its liquid-biopsy technology in the U.

The analysis tool can detect 2, genes associated with tumor biology and results are available only 36 hours following the biopsy collection. Related Link: What's going on with the market today? Benzinga does not provide investment advice. All rights reserved. Nasdaq: BIOCa leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in three upcoming virtual investment conferences:. Yahoo Finance. Sign in.

Sign in to view your mail. Finance Home. Currency in USD. Add to watchlist. Trade prices are not sourced from all markets. Previous Close 5. VolumeMarket Cap Press Releases.

Business Wire. Advertise with us. Data Disclaimer Help Suggestions. Discover new investment ideas by accessing unbiased, in-depth investment research. Day's Range. Beta 5Y Monthly. Earnings Date. Mar 29, Ex-Dividend Date.We have developed a unique, patented methodology to isolate cancer material that is shed into the bloodstream, such as circulating tumor cells, CTCs and cell-free circulating tumor DNA ctDNA.

Because we use a simple blood sample, this molecular information can be obtained non-invasively and more rapidly than a tissue biopsy. Additionally, in patients previously diagnosed with cancer, our liquid biopsy tests offer a solution when a tissue biopsy is insufficient or not possible. Using our proprietary liquid biopsy testing service, physicians can obtain information they need to develop a personalized cancer treatment plan for their patients—all from a simple blood test.

Our liquid biopsies have been used by doctors in thousands of patient cases. We partner with industry leaders and major cancer centers, continually advancing the field of cancer diagnostics. Our CLIA-licensed and CAP-accredited laboratory combines a highly trained professional staff who are experienced in liquid biopsy assay development with innovative instrumentation for optimal test results and quality control.

This development can be performed in our CLIA laboratory. We focus on providing high-level, personalized service to our clients, addressing critical questions of interest to them including:. Contact Customer Service for assistance at Hit enter to search or ESC to close.

Company Overview. At Biocept, we are dedicated to improving outcomes for cancer patients. We focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy. Our experts have spent years working to change the way physicians look at blood in cancer patients.

Licenses and Certifications.

Biocept, Inc. (BIOC)

View License Documentation. Partner with Biocept. Contact us to learn how Biocept can support your research and testing. Contact Us.Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets, and Dunn has over 15 years of commercial marketing experience in the life sciences industry, specializing in diagnostic testing services for oncology.

Our primary mission is to help physicians treat cancer patients more effectively by obtaining actionable information from a simple blood sample to develop personalized treatment plans. Nicholson is a veteran sales executive in the medical lab industry with experience in the oncology segment. Dunn holds post graduate science and education degrees from the University of California, San Diego and Stanford Universityrespectively. In connection with the hiring of Nicholson and Dunn, Biocept granted each individual an inducement stock option award to purchase 24, shares of Biocept common stock.

Each stock option was granted on October 31, in accordance with Biocept's general practice. Each stock option has an exercise price per share equal to the closing price of Biocept's common stock on October 31,and is a non-qualified stock option with a year term. Each stock option is subject to the terms and conditions of Biocept's Amended and Restated Equity Incentive Plan, as amended, and the award agreement pursuant to which the stock option was granted.

In addition, in connection with the hiring of an individual to the position of Product Specialist, Biocept granted such individual an inducement stock option award to purchase 9, shares of Biocept common stock. The stock option was granted on October 31, in accordance with Biocept's general practice.

The stock option has an exercise price per share equal to the closing price of Biocept's common stock on October 31,and it is a non-qualified stock option and has a year term. The stock option is subject to the terms and conditions of Biocept's Amended and Restated Equity Incentive Plan, as amended, and the award agreement pursuant to which the stock option was granted.

Each of the stock options described above was granted as an inducement material to entering into employment with Biocept in accordance with NASDAQ Listing Rule c 4. Biocept, Inc. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options.

For additional information, please visit www. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct.

Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology.

To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, our ability to build upon our market presence in the liquid biopsy segment, and our ability to reaccelerating sales of our Target Selector assay platform, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission SEC filings.

The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

Investor Contact :. Media Contact:. LHA Investor Relations. Jody Cain. Colleen Murphy. Jcain lhai. Skip to main navigation. Print Page.Nasdaq: BIOCa leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces that, as a result of the Company's one-for-ten reverse stock split which will become effective at p.

Eastern Time on September 4,the Company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market "Nasdaq" effective with the open of the market on Tuesday, September 8 Biocept's common shares will continue to trade under the ticker symbol "BIOC.

Authorization for the reverse stock split was approved by the Company's stockholders at Biocept's Annual Meeting of Stockholders. As a result of the reverse stock split, each ten pre-split shares of common stock outstanding will automatically combine and convert to one issued and outstanding share of common stock without any action on the part of the stockholder. No fractional shares of common stock will be issued to any shareholders in connection with the reverse stock split.

Holders of record will receive a cash payment in lieu of fractional shares. For additional information regarding the reverse stock split, please refer to Biocept's Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 4, About Biocept Biocept, Inc. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options.

For additional information, please visit www. Forward-Looking Statements Disclaimer Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct.

Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the reverse stock split, the ability of our tests to provide clinically actionable information and the ability of Biocept's platform to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission SEC filings.

The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. The pre-auction weakness set the tone for the sale -- it saw the smallest bid-to-cover ratio on record. Contrary to the narrative that demand was already stalling, the six-month moving average of foreign interest had been in an uptrend, while the domestic measure was stable.

That suggests the slump in buy orders may be a one-off, with investors likely spooked by the significant volatility on the day. It sells seven-year notes on Thursday. For more articles like this, please visit us at bloomberg. Goldman Sachs and other investment banks have pledged to ease up on junior bankers before. But changing cultural norms is hard work.Why It Matters: Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.

Smaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.

The following three companies have developed technology that could make them sought-after acquisition targets: BioMark Diagnostics Inc OTC: BMKDFa biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technology finds metabolomics biomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas. BioMark is pivoting into commercialization after many years in the research and development phase.

biocept acquisition

On Feb. The collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in Biocept boasts 22 patents for its liquid-biopsy technology in the U. The analysis tool can detect 2, genes associated with tumor biology and results are available only 36 hours following the biopsy collection.

Related Link: What's going on with the market today? Benzinga does not provide investment advice. All rights reserved. Shares of Biocept fell 1.

Biocept, Inc. - BIOC Stock Chart Technical Analysis for 06-22-2020

Under the terms of the agreement, Aegea will provide the assay kit to Biocept for validation at its molecular lab and subsequent commercialization of a laboratory developed test. Financial details of the deal were not disclosed. Biocept is a molecular diagnostic assay provider, while Aegea is focused on developing next-generation nucleic acid technologies.

A key priority will be quantifying viral load to determine how patients are responding to therapy and better assess how infectious they may be. This is an important feature of the test and is especially valuable for identifying asymptomatic patients who have the potential to infect others.

biocept acquisition

Getting target Selector in the hands of other diagnostics companies for validation is a key step for creating more widespread adoption. The two ratings add up to a Moderate Buy consensus rating. The research will be conducted in an independent pathology laboratory setting. Protean BioDiagnostics also expects to validate a laboratory-developed test's analytical performance based on Biocept's EGFR assay test kit. Biocept's molecular assay kit, available for research-use-only and with CE-IVD mark, is used to analyze both formalin-fixed paraffin-embedded tissue samples and circulating tumor DNA from biological fluids.

Yahoo Finance. Sign in.Suppose in the above example we were only interested in Coke, Pepsi, and Sprite.

As pointed out earlier, one way to code the data in that case would be as follows: COKE PEPSI SPRITE. In other words, one variable was created for each soft drink, then a value of 1 was entered into the respective variable whenever the respective drink was mentioned by the respective respondent.

In a sense, we "compact" the three variables Coke, Pepsi, and Sprite into a single variable (Soft Drink) consisting of multiple dichotomies.

All of these types of variables can then be used in crosstabulation tables. For example, we could crosstabulate a multiple dichotomy for Soft Drink (coded as described in the previous paragraph) with a multiple response variable Favorite Fast Foods (with many categories such as Hamburgers, Pizza, etc. As in the frequency table, the percentages and marginal totals in that table can be computed from the total number of respondents as well as the total number of responses.

biocept acquisition

For example, consider the following hypothetical respondent: Gender Coke Pepsi Sprite Food1 Food2 FEMALE 1 1 FISH PIZZA This female respondent mentioned Coke and Pepsi as her favorite drinks, and Fish and Pizza as her favorite fast foods.

In the complete crosstabulation table she will be counted in the following cells of the table: Food. FEMALE MALE COKE PEPSI SPRITE COKE PEPSI SPRITE X X X X 2 2 This female respondent will "contribute" to (i.

Paired Crosstabulation of Multiple Response Variables. A unique option for tabulating multiple response variables is to treat the variables in two or more multiple response variables as matched pairs. Again, this method is best illustrated with a simple example.

Suppose we conducted a survey of past and present home ownership. We asked the respondents to describe their last three (including the present) homes that they purchased.

For each home we asked our respondents to write down the number of rooms in the respective house, and the number of occupants.

We are dedicated to one thing: improving outcomes for cancer patients.

Here is how the data for one respondent (say case number 112) may be entered into a data file: Case no. Rooms 1 2 3 No. Now suppose we wanted to crosstabulate the number of rooms by the number of occupants for all respondents. We can also treat the two factors in this study (Number of Rooms, Number of Occupants) as multiple response variables. However, it would obviously not make any sense to count the example respondent 112 shown above in cell 3 Rooms - 5 Occupants of the crosstabulation table (which we would, if we simply treated the two factors as ordinary multiple response variables).

In other words, we want to ignore the combination of occupants in the third home with the number of rooms in the first home. This is exactly what will be accomplished if we asked for a paired crosstabulation of these multiple response variables.

The best way to verify that one understands the way in which the respective tables are constructed is to crosstabulate some simple example data, and then to trace how each case is counted.

biocept acquisition

The example section of the Crosstabulation chapter in the manual employs this method to illustrate how data are counted for tables involving multiple response variables and multiple dichotomies. To index Statistica 2300 East 14th Street Tulsa, Oklahoma, 74104 (918) 749-1119 Global Sites Find Office StatSoft Benelux StatSoft Bulgaria Ltd.

StatSoft China StatSoft Czech Republic s.


Replies to “Biocept acquisition”

Leave a Reply

Your email address will not be published. Required fields are marked *